2022 World Conference on Lung Cancer (ePosters)-EP08.01-096. Lung Immune Prognostic Index is Prognostic in Patients Treated with PD-1 Inhibitor Combined with Chemotherapy for Non-small Cell Lung Cancer

EP08.01-096. Lung Immune Prognostic Index is Prognostic in Patients Treated with PD-1 Inhibitor Combined with Chemotherapy for Non-small Cell Lung Cancer

Back to course

Pdf Summary

This study focused on the Lung Immune Prognostic Index (LIPI) as a prognostic factor in patients with non-small cell lung cancer (NSCLC) who were treated with a combination of PD-1 inhibitor and chemotherapy. The researchers found that patients with an inferior LIPI score had shorter progression-free survival (PFS) and lower overall response rates (ORR) compared to those with a superior LIPI score. This suggests that LIPI can serve as a predictive biomarker for chemoimmunotherapy in NSCLC.<br /><br />The study included stage III to IV or recurrent NSCLC patients who received first-line immunotherapy plus chemotherapy. LIPI was calculated based on the dNLR (neutrophil count divided by white blood cell count minus neutrophil count) and LDH (lactate dehydrogenase) levels. Complete blood cell counts, LDH, and ALB (albumin) levels were obtained before and after treatment to calculate the PRE-LIPI and POST-LIPI scores.<br /><br />The results showed that patients with inferior LIPI scores had significantly shorter PFS and lower ORR compared to those with superior LIPI scores. This indicates that an inferior LIPI score is associated with a poor prognosis in NSCLC patients treated with chemoimmunotherapy. The researchers conclude that LIPI, which is a simple and accessible clinical biomarker, shows promise as a predictive biomarker for chemoimmunotherapy.<br /><br />In summary, this study demonstrates that LIPI can be a useful tool for predicting the response and prognosis of NSCLC patients treated with a combination of PD-1 inhibitor and chemotherapy. Identifying patients with an inferior LIPI score can help determine those who may benefit less from this treatment approach. Further research and validation of LIPI as a predictive biomarker are warranted.

Asset Subtitle

Anning Xiong

Meta Tag

Speaker Anning Xiong

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

Lung Immune Prognostic Index

LIPI

non-small cell lung cancer

NSCLC

PD-1 inhibitor

chemotherapy

progression-free survival

overall response rates

predictive biomarker

chemoimmunotherapy